Results 11 to 20 of about 72,295 (296)
Dermatology and Therapy, 2023 This Summary of Research overviews the results of the VOLTAIRE-X study (NCT03210259), which looked at what happened when people with plaque psoriasis continually took the adalimumab reference product (adalimumab RP; known by the brand name Humira®) or ...
Alan Menter
doaj +1 more source
Effect of adalimumab on quality of life in patients with active ankylosing spondylitis [PDF]
Xin yixue, 2023 Objective To evaluate the efficacy of adalimumab in improving the quality of life of adult patients with active ankylosing spondylitis （AS）. Methods This was a post-hoc study of the randomized，double-blind controlled clinical trial of adalimumab and ...
Cao Shuangyan, Shao Zhanqin, Gu Jieruo
doaj +1 more source
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
New England Journal of Medicine, 2021 BACKGROUND The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis factor α inhibitor, in patients who have an inadequate response to ...
I. McInnes +13 more
semanticscholar +1 more source
Anti-TNF-Alpha Associated Central Nervous System Demyelination. Drug-Induced Demyelination or Multiple Sclerosis Trigger? A Case Series. [PDF]
Clin Case RepABSTRACT Adalimumab is a monoclonal antibody that targets TNF‐α and is effective in treating several autoimmune disorders, including non‐infectious uveitis; however, it has been associated with demyelinating lesions. This study presents two cases of CNS demyelination in patients who consumed adalimumab. First, an 18‐year‐old man presented with subacute
Abutorabi-Zarchi M, Ziyaei A, Ghane D.
europepmc +2 more sources
Clinical, Cosmetic and Investigational Dermatology, 2023 To date, adalimumab (ADA) is the only biotechnology drug approved for the management of hidradenitis suppurativa (HS), an inflammatory skin condition.
F. Martora +7 more
semanticscholar +1 more source
Frontiers in Pediatrics, 2021 Introduction: Adalimumab is effective in inducing and maintaining remission in children with inflammatory bowel diseases (IBD). Therapeutic drug monitoring is an important strategy to maximize the response rates, but data on the association of serum ...
Marianna Lucafò +10 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Background: From October 2018, adalimumab biosimilars could enter the European market. However, in some countries, such as Netherlands, high discounts reported for the originator product may have influenced biosimilar entry.Objectives: The aim of this ...
Evelien Moorkens +45 more
doaj +1 more source
Annals of the Rheumatic Diseases, 2021 Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active rheumatoid arthritis (RA) despite ongoing treatment with ...
B. Combe +19 more
semanticscholar +1 more source
Clinical and Translational Science, 2021 This study aimed to demonstrate pharmacokinetic (PK) equivalence of a single dose of the proposed adalimumab biosimilar CT‐P17 to United States‐licensed adalimumab (US‐adalimumab) and European Union‐approved adalimumab (EU‐adalimumab). This double‐blind,
Kyung‐Sang Yu +19 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Delanzomib is a novel proteasome inhibitor initially developed for treating multiple myeloma. It was found to inhibit the expression of tumor necrosis factor alpha (TNF-α). This study aimed to investigate the ameliorating effect of delanzomib on collagen-
Lei Wang +5 more
doaj +1 more source